Senti Biosciences, Inc. announced plans to streamline its business operations, including reducing its workforce by approximately 37%, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2701 USD | -6.44% | -9.54% | -59.08% |
May. 17 | Senti Biosciences, Inc. Announces Executive Changes | CI |
May. 09 | Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-59.08% | 12.36M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+2.94% | 22.58B | |
-14.64% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Spark Therapeutics, Inc. Announces Workforce Reduction